Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 Radioembolization + Nivolumab in mCRC
NCT03307603Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nivolumab in metastatic colorectal cancer (mCRC), sponsored by Case Comprehensive Cancer Center. Planned start Dec 2018; status: withdrawn.
02
Drugs
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03307603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307603.